Generic Products (January 2017)

Pharmacy Times, January 2017 Oncology, Volume 83, Issue 1

Read an update on Janary 2017 generic products.

Marketed To: Teva Pharmaceuticals

Compare To: Tribenzor

Indication: Teva has announced the approval of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets, the generic equivalent to Tribenzor, in the United States for the treatment of hypertension to lower blood pressure.

Dosage Form: Tablets: 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg, and 10 mg/40 mg

For More Information: Tevapharm.com

Armodafinil

Marketed By: Breckenridge Pharmaceutical, Inc.

Compare To: Nuvigil

Indication: Breckenridge announced that it has launched its Abbreviated New Drug Application for Armodafinil Tablets, the generic version of Nuvigil. Armodafinil Tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift-work disorder.

Dosage Form: Tablets: 50, 150, and 250 mg

For More Information: bpirx.com

Aripiprazole

Marketed By: Ajanta Pharma USA Inc.

Compare To: Abilify

Indication: Ajanta has announced the launch of Aripiprazole Tablets, USP, the generic version of Abilify, into the US market. The indication is for treatment of symptoms of psychotic conditions, such as schizophrenia, in a wide range of patients.

Dosage Form: Tablets: 2.5, 5, 10, 15, 20, and 30 mg

For More Information: ajantapharmausa.com

Yuvafem

Marketed By: Amneal Pharmaceuticals LLC

Compare To: Vagifem

Indication: Amneal has launched Yuvafem (estradiol vaginal inserts, USP), the first-to-market generic equiv- alent of Vagifem, indicated for the treatment of atrophic vaginitis due to menopause.

Dosage Form: Vaginal tablet: 10 mcg

For More Information: amneal.com